Between 2018 and 2022, Lexaria conducted five human trials of DehydraTECH-CBD in 134 healthy and hypertensive subjects. Credit: Maya Kruchankova / Shutterstock.com.

The US Food and Drug Administration (FDA) has granted clearance for Lexaria Bioscience’s investigational new drug (IND) application to commence the Phase Ib clinical trial, HYPER-H23-1, of DehydraTECH-CBD to treat hypertension.

A drug delivery formulation and processing platform technology of Lexaria,  DehydraTECH-CBD is claimed to boost the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The upcoming double-blind, randomised, placebo-controlled study will assess the safety, pharmacokinetics, and pharmacodynamics of DehydraTECH-CBD in individuals with Stage I or Stage II hypertension.

Assessing the tolerability and safety of the treatment in hypertensive patients is the trial’s primary goal.

The efficacy of DehydraTECH-CBD in reducing blood pressure and detailed pharmacokinetic testing are the secondary objectives of the trial.

Lexaria plans to make further announcements regarding the commencement of the trial, which is contingent on securing adequate funding.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Between 2018 and 2022, Lexaria conducted five human clinical trials involving DehydraTECH-CBD in 134 healthy and hypertensive subjects.

These studies did not record any serious adverse events and indicated a substantial decline in resting blood pressure across acute and multi-week dosing regimens.

Notably, results from Lexaria’s study dubbed HYPER-H21-4 revealed a potentially new mechanism of action of DehydraTECH-CBD in reducing blood pressure, which may be partially explained by its interaction with the human sympatho-chromaffin system through catestatin modulation.

Lexaria president John Docherty said: “This is a significant milestone achievement for Lexaria demonstrating, for the first time, that its DehydraTECH technology meets the FDA’s high level of regulatory scrutiny sufficient to formally commence US registrational clinical testing towards possible future pharmaceutical commercialisation.

“We look forward to commencing this important clinical trial and building upon the wealth of early-stage clinical data we have gathered and presented to the FDA to date, demonstrating the safety, efficacy and novel mechanistic performance of DehydraTECH-CBD in hypertensive patients.”